PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › L-fucose

Drugs in development · updated 30 October 2026

L-fucose: clinical trials and development status

Other names and codes: AVTX-803

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Jan 2028 – Nov 2028 (Phuturdex estimate)

As of 30 October 2026 L-fucose is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is III.

3Active trials
IIIMost advanced phase
2Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow L-fucose and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Leukocyte adhesion deficiency type 1III2NCT05462587
Glut1 Deficiency SyndromeII1NCT07432490

Everything on L-fucose

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch